Core Viewpoint - BridgeBio Pharma, Inc. has announced the pricing of $550 million in 0.75% convertible senior notes due 2033, aimed at raising funds for various corporate purposes, including repurchasing existing convertible notes and shares [1][3][8]. Group 1: Offering Details - The offering consists of $550 million aggregate principal amount of 0.75% convertible senior notes, with an option for initial purchasers to buy an additional $82.5 million [1][2]. - The expected net proceeds from the sale are approximately $538.4 million, or $619.3 million if the option is fully exercised [2]. - The notes will bear interest at a rate of 0.75% per year, payable semi-annually, and will mature on February 1, 2033 [5][8]. Group 2: Use of Proceeds - The net proceeds will be used to repurchase or settle obligations related to the Company's 2.50% convertible senior notes due 2027 and for general corporate purposes [3]. - Approximately $82.5 million of cash on hand will be used to repurchase about 1.1 million shares of common stock from certain purchasers of the notes [4]. Group 3: Conversion and Redemption Terms - The initial conversion rate is set at 9.0435 shares per $1,000 principal amount of notes, equating to an initial conversion price of approximately $110.58 per share, representing a 45% premium over the last reported sale price of $76.26 [6][8]. - The Company may redeem the notes starting February 6, 2030, under certain conditions, at a redemption price equal to 100% of the principal amount plus accrued interest [7][10]. Group 4: Company Overview - BridgeBio Pharma is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [13].

Core Viewpoint - BridgeBio Pharma, Inc. plans to offer $550 million in convertible senior notes due 2033 to strengthen its balance sheet, lower interest expenses, reduce dilution, and extend debt maturity [1] Group 1: Offering Details - The offering will be made to qualified institutional buyers under Rule 144A of the Securities Act [1] - The company may grant initial purchasers an option to buy an additional $82.5 million in notes [1] - The final terms of the notes, including interest rate and conversion rate, will be determined at pricing [4] Group 2: Use of Proceeds - Net proceeds from the offering will be used to repurchase or settle obligations related to the company's 2.50% convertible senior notes due 2027 and for general corporate purposes [2] - Up to $82.5 million of cash on hand will be used to repurchase shares of common stock from certain purchasers of the notes [3] Group 3: Notes Characteristics - The notes will bear interest semi-annually and mature on February 1, 2033, with specific conditions for conversion prior to November 1, 2032 [4] - The company may redeem the notes starting February 6, 2030, under certain conditions [5] - The notes will rank senior in right of payment to subordinated unsecured indebtedness and will be structurally junior to all subsidiary liabilities [6] Group 4: Company Overview - BridgeBio Pharma, Inc. focuses on developing transformative medicines for genetic diseases, with a pipeline ranging from early science to advanced clinical trials [9]

Core Viewpoint - Plug Power Inc. plans to offer $375 million in Convertible Senior Notes due 2033, with an option for an additional $56.25 million, to qualified institutional buyers, subject to market conditions [1][5] Group 1: Offering Details - The offering will be conducted under Rule 144A of the Securities Act of 1933, and the completion of the offering is uncertain [1][5] - The notes will be unsecured obligations of Plug Power, ranking senior to future subordinated debts and equal to existing liabilities, but junior to secured debts [4] Group 2: Use of Proceeds - Approximately $243 million of the net proceeds will be used to repay the outstanding principal and interest on 15.00% secured debentures, along with related termination fees [2] - Remaining proceeds will fund the repurchase of existing 7.00% Convertible Senior Notes due 2026 and for general corporate purposes [2] Group 3: Note Repurchase Transactions - Plug Power intends to negotiate cash repurchase transactions for the 2026 notes with holders, with terms dependent on market conditions [3] - The repurchase activities may influence the market price of Plug Power's common stock [3]